Although dual antiplatelet therapy using cilostazol is associated with a lower risk of recurrent stroke in men, it has no significant benefit for women, a sub-analysis of CSPS.com results suggests.

When cilostazol is given orally, its plasma concentrations reach a maximum after 3 to 4 hours, and the plasma concentration is not altered by oral administration twice a day.

Cilostazol given prior to a surgical procedure resulted in a safer transition off to dual antiplatelet therapy (DAPT) by reducing the risk the risk of bleeding during the operation in patients ...

SAN DIEGO — The most quoted research publications are those that address clinically frustrating scenarios for which we have no answer. Charles Laham, MD, FSCAI, and colleagues attempted to ...

The antiplatelet drug cilostazol (which prevents the blood from clotting) works as well as, and might be better than, aspirin in helping to prevent a secondary stroke in Asian patients, but with ...

Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke Date: February 6, 2019 Source: American Heart Association Summary: The long-term combination of cilostazol with aspirin or ...

Both cilostazol and isosorbide mononitrate, she noted, are widely available around the world, and inexpensive. Philip Bath, MD (University of Nottingham, England), whose presentation focused on ...

Cilostazol is associated with increased heart rate, and in the relatively high proportion of ACS patients in CILON-T, this side effect may have contributed to increased event rates. Importantly, the ...

In patients with femoropopliteal lesions, additional treatment with cilostazol after implantation of a drug-eluting stent is associated with significantly lower restenosis rates at 1 year, ...

For patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), adjunctive loading dose of cilostazol is not associated with prevention of periprocedural ...

Cilostazol tablets are the AB-rated generic equivalent of Otsuka America Pharmaceutical's Pletal tablets. Teva said the shipment of Cilostazol is expected to begin immediately.

Cilostazol inhibited insulin-induced and LXR-agonist-induced expression of SREBP-1c and its downstream targets, acetyl-CoA carboxylase and fatty acid synthase, in cultured hepatocytes.